For example, in Grade II and III gliomas, survival outcomes vary significantly on the basis of the interplay between TERTp mutations, MGMT methylation, IDH mutation, and 1p/19q codeletion.121 Notably, patients with IDH mutant gliomas and concurrent TERTp mutations have poorer prognoses than those with IDH mutations alone, underscoring the complex molecular interactions governing glioma progression. The gene discussed is IDH1; the disease is central nervous system cancer.